“…Historically, 99m Tc-pertechnetate has been the radiopharmaceutical of choice for the scintigraphic evaluation of the parotid gland, including both functional disorders and neoplasms, particularly Warthin tumor 1 . Warthin tumors are benign and slow-growing neoplasms that demonstrate hypervascularity and pertechnetate avidity 1,2 . The sensitivity and specificity of detecting Warthin tumor on pertechnetate scintigraphy are 78% and 91%, respectively 3 .…”